AstraZeneca’s ZD4054 Phase II Shows 24.5-Month Overall Survival In Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Median survival rates in metastatic hormone-resistant prostate cancer improve on Taxotere by more than five months; Phase III trials of ZD4054 will begin this year.